Last reviewed · How we verify
Autologous CD7-targeting CAR T cells
Autologous CD7-targeting CAR T cells is a CAR T cell therapy Biologic drug developed by Hebei Senlang Biotechnology Inc., Ltd.. It is currently in Phase 2 development for T-cell acute lymphoblastic leukemia (T-ALL), Peripheral T-cell lymphomas.
Autologous CD7-targeting CAR T cells are engineered patient-derived T cells that recognize and kill CD7-expressing cells, primarily used to target T-cell malignancies.
Autologous CD7-targeting CAR T cells are engineered patient-derived T cells that recognize and kill CD7-expressing cells, primarily used to target T-cell malignancies. Used for T-cell acute lymphoblastic leukemia (T-ALL), Peripheral T-cell lymphomas.
At a glance
| Generic name | Autologous CD7-targeting CAR T cells |
|---|---|
| Sponsor | Hebei Senlang Biotechnology Inc., Ltd. |
| Drug class | CAR T cell therapy |
| Target | CD7 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
This therapy involves extracting T cells from a patient, genetically engineering them to express a chimeric antigen receptor (CAR) that targets CD7 (a surface antigen on T cells), and reinfusing the modified cells to recognize and eliminate CD7+ malignant T cells. CD7 is highly expressed on T-cell acute lymphoblastic leukemia (T-ALL) and peripheral T-cell lymphomas, making it an attractive target for CAR T cell therapy.
Approved indications
- T-cell acute lymphoblastic leukemia (T-ALL)
- Peripheral T-cell lymphomas
Common side effects
- Cytokine release syndrome
- Neurotoxicity
- Cytopenias
- Infections
Key clinical trials
- To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT (PHASE1)
- Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL. (PHASE2)
- To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL (PHASE1)
- Multi-omics Profiling of Patients With Aplastic Anemia Before and After CD7-CAR-T Therapy
- Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies (PHASE1)
- CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study (PHASE1)
- Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies (PHASE1)
- Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Autologous CD7-targeting CAR T cells CI brief — competitive landscape report
- Autologous CD7-targeting CAR T cells updates RSS · CI watch RSS
- Hebei Senlang Biotechnology Inc., Ltd. portfolio CI
Frequently asked questions about Autologous CD7-targeting CAR T cells
What is Autologous CD7-targeting CAR T cells?
How does Autologous CD7-targeting CAR T cells work?
What is Autologous CD7-targeting CAR T cells used for?
Who makes Autologous CD7-targeting CAR T cells?
What drug class is Autologous CD7-targeting CAR T cells in?
What development phase is Autologous CD7-targeting CAR T cells in?
What are the side effects of Autologous CD7-targeting CAR T cells?
What does Autologous CD7-targeting CAR T cells target?
Related
- Drug class: All CAR T cell therapy drugs
- Target: All drugs targeting CD7
- Manufacturer: Hebei Senlang Biotechnology Inc., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for T-cell acute lymphoblastic leukemia (T-ALL)
- Indication: Drugs for Peripheral T-cell lymphomas
- Compare: Autologous CD7-targeting CAR T cells vs similar drugs
- Pricing: Autologous CD7-targeting CAR T cells cost, discount & access